3.31
Puma Biotechnology Inc stock is traded at $3.31, with a volume of 258.64K.
It is up +0.00% in the last 24 hours and up +2.32% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$3.31
Open:
$3.33
24h Volume:
258.64K
Relative Volume:
0.74
Market Cap:
$178.70M
Revenue:
$230.47M
Net Income/Loss:
$30.28M
P/E Ratio:
5.4262
EPS:
0.61
Net Cash Flow:
$38.86M
1W Performance:
-2.65%
1M Performance:
+2.32%
6M Performance:
+5.08%
1Y Performance:
+5.41%
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PBYI
Puma Biotechnology Inc
|
3.31 | 178.70M | 230.47M | 30.28M | 38.86M | 0.61 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
Jun-25-20 | Resumed | BofA/Merrill | Underperform |
Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
May-10-19 | Downgrade | Citigroup | Buy → Neutral |
Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
Sep-17-18 | Initiated | Goldman | Sell |
May-11-18 | Reiterated | Stifel | Buy |
Nov-10-17 | Reiterated | Citigroup | Buy |
Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
Oct-02-17 | Reiterated | Stifel | Buy |
Sep-11-17 | Reiterated | Credit Suisse | Outperform |
Jul-10-17 | Resumed | Leerink Partners | Outperform |
Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Puma Biotechnology Holds Annual Stockholders Meeting 2025 - TipRanks
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance
With 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backing - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by Squarepoint Ops LLC - Defense World
78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial Corp - Defense World
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 - BioSpace
Puma Biotechnology Awards Key Talent with 18,250 RSUs in Strategic Retention Move - Stock Titan
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors - sharewise
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st
Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Puma Biotechnology Inc (PBYI) Forecast: Revisiting The Past To Gain Insights For The Future - Stocksregister
Puma Biotechnology's (NASDAQ:PBYI) Earnings Are Of Questionable Quality - Yahoo Finance
Puma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic efforts - MSN
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Bought by Wells Fargo & Company MN - Defense World
Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock - Nasdaq
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates - MSN
Puma Biotechnology First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2025 Earnings Call Transcript - Insider Monkey
Puma Biotech CCO Jeff Ludwig departs, no replacement named By Investing.com - Investing.com Canada
Puma Biotech CCO Jeff Ludwig departs, no replacement named - Investing.com
Puma Biotechnology, Inc. Announces Termination of Jeff J. Ludwig as Chief Commercial Officer - marketscreener.com
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? - Yahoo Finance
Puma Biotechnology Terminates Chief Commercial Officer - TipRanks
Puma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges By GuruFocus - Investing.com Canada
Puma Biotechnology Reports Positive Q1 2025 Earnings - TipRanks
Puma Biotech Q1 2025 slides: NERLYNX revenue up 7% YoY despite quarterly decline - Investing.com Canada
Puma Biotech: Q1 Earnings Snapshot - The Washington Post
Cautious Hold Rating on Puma Biotechnology Amid Declining Sales and Uncertain Trial Outcomes - TipRanks
Earnings call transcript: Puma Biotech Q1 2025 results miss forecasts By Investing.com - Investing.com UK
Puma Biotechnology Reports First Quarter Financial Results - BioSpace
Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Earnings call transcript: Puma Biotech Q1 2025 results miss forecasts - Investing.com
Check out these key findings about Puma Biotechnology Inc (PBYI) - Sete News
Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients - The Manila Times
Er-Kim Announces Exclusive Distribution Agreement with Puma - GlobeNewswire
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 - Yahoo Finance
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Puma Biotechnology Inc Stock (PBYI) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Stuglik Brian M | Director |
Jun 13 '25 |
Sale |
3.39 |
8,100 |
27,459 |
94,958 |
Senderowicz Adrian | Director |
Jun 13 '25 |
Sale |
3.40 |
27,000 |
91,800 |
27,000 |
MOYES JAY M | Director |
Jun 13 '25 |
Sale |
3.40 |
22,000 |
74,800 |
53,322 |
Dorval Allison | Director |
Jun 13 '25 |
Sale |
3.40 |
11,610 |
39,474 |
75,390 |
Cesano Alessandra | Director |
Jun 13 '25 |
Sale |
3.40 |
12,150 |
41,310 |
68,850 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):